A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
Crossref DOI link: https://doi.org/10.1245/s10434-017-5921-4
Published Online: 2017-06-12
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Okano, Keiichi
Suto, Hironobu
Oshima, Minoru
Maeda, Eri
Yamamoto, Naoki
Kakinoki, Keitaro
Kamada, Hideki
Masaki, Tsutomu
Takahashi, Shigeo
Shibata, Toru
Suzuki, Yasuyuki
License valid from 2017-06-12